MOLECULAR INSIGHT PHARMACEUTICAL
			Symbol			MIPI

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

Molecular Insight Pharmaceuticals Presents Azedra(TM) 12-Month Efficacy Data From Phase I Clinical Trial in Neuroendocrine Tumors

2009-10-05 08:34 ET - News Release

CAMBRIDGE, MA -- (MARKET WIRE) -- 10/05/09

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) today reported one-year follow-up data from a Phase I dose-escalation clinical study of Azedra(TM) demonstrating a positive safety profile and durable objective tumor responses in patients with neuroendocrine cancers, pheochromocytoma and paraganglioma. The study was designed to evaluate the safety and identify the maximum tolerated dose (MTD) of Azedra, as well as to collect clinical data on efficacy. These data were presented on October 2, 2009, at the North American Neuroendocrine Tumor Society (NANETS) 2009 Neuroendocrine Tumor Symposium in Charlotte, North Carolina. Azedra (Ultratrace™ iobenguane I 131) is Molecular Insight's lead oncology targeted radiotherapeutic using the Company's proprietary radiolabeling technology platform.

The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try, click here for a free 30 day trial subscription.